Kraj: Kanada
Język: angielski
Źródło: Health Canada
ABOBOTULINUMTOXINA
IPSEN BIOPHARMACEUTICALS CANADA INC
M03AX01
BOTULINUM TOXIN
300UNIT
POWDER FOR SOLUTION
ABOBOTULINUMTOXINA 300UNIT
INTRAMUSCULAR
3ML
Prescription
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Active ingredient group (AIG) number: 0153614001; AHFS:
APPROVED
2017-01-03
_Dysport Aesthetic_ _®_ _ _ _Page 1 of 26_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DYSPORT AESTHETIC ® abobotulinumtoxinA Sterile lyophilized powder for solution for injection 300 Units per vial Neuromuscular Blocking Agent Ipsen Biopharmaceuticals Canada Inc. 5050 Satellite Drive, Suite 500 Mississauga, ON L4W 0G1 Date of Initial Authorization: FEB 19, 2013 Date of Revision: SEP 5, 2023 Distributed by: Galderma Canada Inc. 55 Commerce Valley Drive West Thornhill, ON L3T 7V9 Submission Control Number: 273398 _ _ _Dysport Aesthetic_ _®_ _ (abobotulinumtoxinA) _ _Page 2 of 26_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 03/2022 3 Serious Warnings and Precautions Box 08/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................... 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations .......................................................................................... 5 4.2 Recommended Dose and Dosage Ad Przeczytaj cały dokument